EP1409655A4 - Immunoglobulin superfamily proteins - Google Patents

Immunoglobulin superfamily proteins

Info

Publication number
EP1409655A4
EP1409655A4 EP02726671A EP02726671A EP1409655A4 EP 1409655 A4 EP1409655 A4 EP 1409655A4 EP 02726671 A EP02726671 A EP 02726671A EP 02726671 A EP02726671 A EP 02726671A EP 1409655 A4 EP1409655 A4 EP 1409655A4
Authority
EP
European Patent Office
Prior art keywords
immunoglobulin superfamily
superfamily proteins
proteins
immunoglobulin
superfamily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02726671A
Other languages
German (de)
French (fr)
Other versions
EP1409655A2 (en
Inventor
Henry Yue
Yuming Xu
Kavitha Thangavelu
Bridget A Warren
Y Tom Tang
Brendan M Duggan
Uyen K Tran
Mariah R Baughn
Cynthia D Honchell
Neil Burford
Ian J Forsythe
Junming Yang
Patricia M Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Publication of EP1409655A2 publication Critical patent/EP1409655A2/en
Publication of EP1409655A4 publication Critical patent/EP1409655A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
EP02726671A 2001-03-12 2002-03-12 Immunoglobulin superfamily proteins Withdrawn EP1409655A4 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US27524901P 2001-03-12 2001-03-12
US275249P 2001-03-12
US31681001P 2001-08-31 2001-08-31
US316810P 2001-08-31
US32397701P 2001-09-21 2001-09-21
US323977P 2001-09-21
US34844701P 2001-10-26 2001-10-26
US348447P 2001-10-26
US34388001P 2001-11-02 2001-11-02
US343880P 2001-11-02
PCT/US2002/009052 WO2002072794A2 (en) 2001-03-12 2002-03-12 Immunoglobulin superfamily proteins

Publications (2)

Publication Number Publication Date
EP1409655A2 EP1409655A2 (en) 2004-04-21
EP1409655A4 true EP1409655A4 (en) 2005-04-06

Family

ID=27540591

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02726671A Withdrawn EP1409655A4 (en) 2001-03-12 2002-03-12 Immunoglobulin superfamily proteins

Country Status (5)

Country Link
EP (1) EP1409655A4 (en)
JP (1) JP2004533222A (en)
AU (1) AU2002257088A1 (en)
CA (1) CA2440618A1 (en)
WO (1) WO2002072794A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
MXPA04001986A (en) * 2001-08-29 2004-06-07 Genentech Inc Compositions and methods for the treatment of immune related diseases.
WO2004000221A2 (en) * 2002-06-20 2003-12-31 The Regents Of The University Of California Compositions and methods for modulating lymphocyte activity
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
WO2004039394A1 (en) * 2002-10-25 2004-05-13 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US20040109863A1 (en) * 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
US20040248257A1 (en) * 2003-04-30 2004-12-09 The Scripps Research Institute SPEX compositions and methods of use
CA2586615C (en) * 2004-11-12 2017-06-27 Genentech, Inc. Pro87299 (btla), and variants thereof, for treating immune related disorders
US8188232B1 (en) 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
US9708404B2 (en) 2012-12-21 2017-07-18 Seattle Genetics, Inc. Anti-NTB-A antibodies and related compositions and methods
WO2015039212A1 (en) 2013-09-17 2015-03-26 University Health Network (Uhn): Technology Development And Commercialization Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment
EP2905622A1 (en) * 2014-02-07 2015-08-12 Institut D'Investigaciones Biomédiques August Pi i Sunyer Diagnosis of a neurological disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
WO2000055371A1 (en) * 1999-03-18 2000-09-21 Human Genome Sciences, Inc. 27 human secreted proteins
WO2001040466A2 (en) * 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001068848A2 (en) * 2000-03-01 2001-09-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002000691A2 (en) * 2000-06-27 2002-01-03 Curagen Corporation Polynucleotides and polypeptides encoded thereby
WO2002062999A2 (en) * 2000-12-29 2002-08-15 Curagen Corporation Proteins and nucleic acids encoding same
WO2002099040A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Igs as modifiers of the p53 pathway and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
WO2000055371A1 (en) * 1999-03-18 2000-09-21 Human Genome Sciences, Inc. 27 human secreted proteins
WO2001040466A2 (en) * 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001068848A2 (en) * 2000-03-01 2001-09-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002000691A2 (en) * 2000-06-27 2002-01-03 Curagen Corporation Polynucleotides and polypeptides encoded thereby
WO2002062999A2 (en) * 2000-12-29 2002-08-15 Curagen Corporation Proteins and nucleic acids encoding same
WO2002099040A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Igs as modifiers of the p53 pathway and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 14 July 2000 (2000-07-14), "601194074F1 NIH_MGC_7 Homo sapiens cDNA clone IMAGE:3537763 5', mRNA sequence.", XP002304382, retrieved from EBI accession no. EM_PRO:BE264969 Database accession no. BE264969 *
DATABASE EMBL [online] 18 April 1997 (1997-04-18), "EST59829 Infant brain Homo sapiens cDNA 5' end.", XP002304381, retrieved from EBI accession no. EM_PRO:AA351918 Database accession no. AA351918 *
DATABASE EMBL [online] 21 November 2002 (2002-11-21), "Homo sapiens NPEH2 (NEPH2) mRNA, complete cds.", XP002304383, retrieved from EBI accession no. EM_PRO:AF480410 Database accession no. AF480410 *
DATABASE EMBL [online] 3 December 1999 (1999-12-03), "Homo sapiens genomic DNA, chromosome 11q, clone:RP11-713C6.", XP002304380, retrieved from EBI accession no. EM_HUM:AP000806 Database accession no. AP000806 *
SELLIN LORENZ ET AL: "NEPH1 defines a novel family of podocin interacting proteins.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. JAN 2003, vol. 17, no. 1, January 2003 (2003-01-01), pages 115 - 117, XP002304379, ISSN: 1530-6860 *

Also Published As

Publication number Publication date
AU2002257088A1 (en) 2002-09-24
EP1409655A2 (en) 2004-04-21
CA2440618A1 (en) 2002-09-19
JP2004533222A (en) 2004-11-04
WO2002072794A3 (en) 2004-01-29
WO2002072794A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
GB0130228D0 (en) Protein
EP1365022A4 (en) Adiponectin-associated protein
GB0130557D0 (en) Proteins
GB0108079D0 (en) Protein
EP1409655A4 (en) Immunoglobulin superfamily proteins
GB0130720D0 (en) Proteins
AU2002219974A1 (en) Immunoglobulin superfamily proteins
EP1373306A4 (en) Cytoskeletion-associated proteins
GB0128161D0 (en) Receptor protein
AU2002326909A8 (en) Neurotransmission-associated proteins
GB0130560D0 (en) Proteins
GB0130721D0 (en) Protein
GB0106318D0 (en) Protein
GB0130743D0 (en) Proteins
GB0128374D0 (en) Proteins
GB0128487D0 (en) Proteins
GB0128596D0 (en) Proteins
GB0130384D0 (en) Proteins
GB0126787D0 (en) Proteins
GB0125514D0 (en) Proteins
GB0130718D0 (en) Proteins
GB0130719D0 (en) Proteins
GB0114313D0 (en) Proteins
GB0130722D0 (en) Proteins
GB0130742D0 (en) Proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030924

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/12 B

Ipc: 7C 07K 14/47 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050512